TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multimodal Opiate-sparing Analgesia Versus Traditional Opiate Based Analgesia After Cardiac Surgery, a Randomized Controlled Trial
Brief Summary: To test if multimodal analgesia with different analgesic medication offer better pain relief, lesser side effects and is safe compared to conventionel opiod analgesia after cardiac surgery.


Options:
A: Arm Label: A, 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: A, 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethason Helvepharm ® | Intervention Type: DRUG; Name: Dexamethason Helvepharm ®; Assigned to Arm(s): A, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A, 1
B: Arm Label: Multimodal; Type: EXPERIMENTAL; Interventions: Drug: Ibuprofen, Drug: Gabapentin, Drug: Paracetamol | Arm Label: Morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine, Drug: Paracetamol | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Multimodal | Intervention Type: DRUG; Name: Gabapentin; Assigned to Arm(s): Multimodal | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Morphine | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Morphine, Multimodal
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Arm Label: Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Placebo
D: Arm Label: 8 mg dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: Placebo, saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: 40 mg dexamethasone; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): 40 mg dexamethasone, 8 mg dexamethasone, Placebo, saline

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multimodal Opiate-sparing Analgesia Versus Traditional Opiate Based Analgesia After Cardiac Surgery, a Randomized Controlled Trial
Brief Summary: To test if multimodal analgesia with different analgesic medication offer better pain relief, lesser side effects and is safe compared to conventionel opiod analgesia after cardiac surgery.


Options:
A: Arm Label: Multimodal; Type: EXPERIMENTAL; Interventions: Drug: Ibuprofen, Drug: Gabapentin, Drug: Paracetamol | Arm Label: Morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine, Drug: Paracetamol | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Multimodal | Intervention Type: DRUG; Name: Gabapentin; Assigned to Arm(s): Multimodal | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Morphine | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Morphine, Multimodal
B: Arm Label: Active Clonidine and Active ASA; Type: EXPERIMENTAL; Interventions: Drug: Active Clonidine, Drug: Active ASA | Arm Label: Active Clonidine and Placebo ASA; Type: EXPERIMENTAL; Interventions: Drug: Active Clonidine, Drug: Placebo ASA | Arm Label: Placebo Clonidine and Active ASA; Type: EXPERIMENTAL; Interventions: Drug: Placebo Clonidine, Drug: Active ASA | Arm Label: Placebo Clonidine and Placebo ASA; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Clonidine, Drug: Placebo ASA | Intervention Type: DRUG; Name: Active Clonidine; Assigned to Arm(s): Active Clonidine and Active ASA, Active Clonidine and Placebo ASA | Intervention Type: DRUG; Name: Placebo Clonidine; Assigned to Arm(s): Placebo Clonidine and Active ASA, Placebo Clonidine and Placebo ASA | Intervention Type: DRUG; Name: Active ASA; Assigned to Arm(s): Active Clonidine and Active ASA, Placebo Clonidine and Active ASA | Intervention Type: DRUG; Name: Placebo ASA; Assigned to Arm(s): Active Clonidine and Placebo ASA, Placebo Clonidine and Placebo ASA
C: Arm Label: intravenous ibuprofen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous ibuprofen | Arm Label: normal saline; Type: PLACEBO_COMPARATOR; Interventions: Other: Normal saline as placebo comparator | Intervention Type: OTHER; Name: Normal saline as placebo comparator; Assigned to Arm(s): normal saline | Intervention Type: DRUG; Name: Intravenous ibuprofen; Assigned to Arm(s): intravenous ibuprofen
D: Arm Label: Ketorolac; Type: EXPERIMENTAL; Interventions: Drug: Ketorolac | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ketorolac; Assigned to Arm(s): Ketorolac | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multimodal Opiate-sparing Analgesia Versus Traditional Opiate Based Analgesia After Cardiac Surgery, a Randomized Controlled Trial
Brief Summary: To test if multimodal analgesia with different analgesic medication offer better pain relief, lesser side effects and is safe compared to conventionel opiod analgesia after cardiac surgery.


Options:
A: Arm Label: Multimodal; Type: EXPERIMENTAL; Interventions: Drug: Ibuprofen, Drug: Gabapentin, Drug: Paracetamol | Arm Label: Morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine, Drug: Paracetamol | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Multimodal | Intervention Type: DRUG; Name: Gabapentin; Assigned to Arm(s): Multimodal | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Morphine | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Morphine, Multimodal
B: Intervention Type: OTHER; Name: Mild intraoperative hypercapnia (50 mmHg vs. 30 mmHg); Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: Supplemental oxygen (80% vs. 30%); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
C: Arm Label: A, 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: A, 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethason Helvepharm ® | Intervention Type: DRUG; Name: Dexamethason Helvepharm ®; Assigned to Arm(s): A, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A, 1
D: Arm Label: dexamethasone; Type: N/A; Interventions: N/A | Arm Label: placebo; Type: N/A; Interventions: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SWIFT: Study of Women, Infant Feeding and Type 2 Diabetes After GDM Pregnancy
Brief Summary: The overall goal of the Study of Women, Infant Feeding and Type 2 Diabetes after GDM pregnancy (SWIFT) is to determine the relation of longer and more intensive lactation, as compared to formula feeding, on progression to incident type 2 diabetes mellitus among women within several years following delivery of a GDM pregnancy. The initial study enrolled women with recent GDM at 6 to 9 weeks post-delivery to reclassify oral glucose tolerance and conduct subsequent testing of glucose tolerance to ascertain progression to overt diabetes up to two years later. Research methods were utilized to assess lactation intensity and duration quantitatively and to evaluate incidence rates of diabetes, as well as changes in blood glucose levels, insulin resistance, body weight, waist circumference, and overall adiposity from baseline and up to several years later. SWIFT is a prospective, observational cohort study of 1,035 women recruited during pregnancy who were diagnosed with gestational diabetes mellitus (GDM) via Carpenter and Coustan criteria and enrolled into the research study. We assessed the natural history of progression to prediabetes and type 2 diabetes from early postpartum for a racially and ethnically diverse cohort of women with GDM (75% minority) at high-risk for developing overt diabetes within 5-10 years post-delivery.


Options:
A: Arm Label: Women with recent GDM pregnancy; Type: N/A; Interventions: N/A
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metoclopramide (Maxolon) | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metoclopramide (Maxolon) | Arm Label: D; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Metoclopramide (Maxolon); Assigned to Arm(s): A, C | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B, D
C: Arm Label: Still-Tee; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Still-Tee | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Still-Tee | Arm Label: Water; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Still-Tee; Assigned to Arm(s): Placebo, Still-Tee
D: Intervention Type: DRUG; Name: domperidone; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Examining the Effects of Diet on Health With an Online Program
Brief Summary: The study is a pilot, designed to provide data regarding the feasibility and acceptability of conducting such a study on a larger scale. The present study is a randomized controlled clinical trial comparing two programs to help people manage diabetes and lose weight, one using a moderate-carbohydrate diet promoted by the American Diabetes Association (ADA) and the other using on a low-carbohydrate diet (LC) and mindfulness and positive affect lifestyle modifications. Intervention content will include information about nutrition (American Diabetes Association recommended diet or carbohydrate restriction) and, in the LC group, emotion regulation, positive affect, and mindful eating strategies.


Options:
A: Intervention Type: BEHAVIORAL; Name: Four Diets Differing in Macronutrient Composition; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Diets Low in Saturated Fat; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Low Carbohydrate Diet; Assigned to Arm(s): N/A
C: Arm Label: American Diabetes Association recommended diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: American Diabetes Association Diet | Arm Label: Low Carbohydrate Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral: Low Carbohydrate, Ketogenic Diet, Behavioral: Mindfulness and Positive Affect Skills | Intervention Type: BEHAVIORAL; Name: Behavioral: Low Carbohydrate, Ketogenic Diet; Assigned to Arm(s): Low Carbohydrate Diet | Intervention Type: BEHAVIORAL; Name: American Diabetes Association Diet; Assigned to Arm(s): American Diabetes Association recommended diet | Intervention Type: BEHAVIORAL; Name: Mindfulness and Positive Affect Skills; Assigned to Arm(s): Low Carbohydrate Diet
D: Arm Label: Low carbohydrate diet (F); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Low carbohydrate - high fat diet | Arm Label: Traditional diet (K); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: High carbohydrate - low fat diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Low carbohydrate - high fat diet; Assigned to Arm(s): Low carbohydrate diet (F) | Intervention Type: DIETARY_SUPPLEMENT; Name: High carbohydrate - low fat diet; Assigned to Arm(s): Traditional diet (K)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Registry Study of Stenting for Symptomatic Intracranial Artery Stenosis in China-a Prospective Multicenter Registry Study
Brief Summary: The SAMMPRIS suggested that aggressive treatment was superior to intravascular stenting in patients with severe symptomatic intracranial atherosclerotic stenosis (ICAS) due to high complication rate in patients in stenting group. However the intravascular therapy is going on because of low complication rate in considerable Chinese studies coming from several high volume stroke centers. Given to 12.2% patients failing to aggressive medical therap in the SAMMPRIS study, it is imperative to performing an multiple prospective registry study of stenting for patients with ICAS in China.


Options:
A: Arm Label: intensive medical management plus stenting; Type: EXPERIMENTAL; Interventions: Device: intracranial angioplasty and stenting | Arm Label: intensive medical management alone; Type: EXPERIMENTAL; Interventions: Other: intensive medical management | Intervention Type: DEVICE; Name: intracranial angioplasty and stenting; Assigned to Arm(s): intensive medical management plus stenting | Intervention Type: OTHER; Name: intensive medical management; Assigned to Arm(s): intensive medical management alone
B: Arm Label: Intracranial stenting group; Type: EXPERIMENTAL; Interventions: Procedure: Intracranial stenting group | Arm Label: medical group; Type: ACTIVE_COMPARATOR; Interventions: Drug: medical group | Intervention Type: PROCEDURE; Name: Intracranial stenting group; Assigned to Arm(s): Intracranial stenting group | Intervention Type: DRUG; Name: medical group; Assigned to Arm(s): medical group
C: Arm Label: aggressive medical treatment; Type: N/A; Interventions: Device: intravascular stent therapy | Intervention Type: DEVICE; Name: intravascular stent therapy; Assigned to Arm(s): aggressive medical treatment
D: Arm Label: Antiplatelet; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin, Drug: clopidogrel, Other: placebo | Arm Label: Blood pressure; Type: ACTIVE_COMPARATOR; Interventions: Other: Target of Blood Pressure | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): Antiplatelet | Intervention Type: DRUG; Name: clopidogrel; Assigned to Arm(s): Antiplatelet | Intervention Type: OTHER; Name: Target of Blood Pressure; Assigned to Arm(s): Blood pressure | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Antiplatelet

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Registry Study of Stenting for Symptomatic Intracranial Artery Stenosis in China-a Prospective Multicenter Registry Study
Brief Summary: The SAMMPRIS suggested that aggressive treatment was superior to intravascular stenting in patients with severe symptomatic intracranial atherosclerotic stenosis (ICAS) due to high complication rate in patients in stenting group. However the intravascular therapy is going on because of low complication rate in considerable Chinese studies coming from several high volume stroke centers. Given to 12.2% patients failing to aggressive medical therap in the SAMMPRIS study, it is imperative to performing an multiple prospective registry study of stenting for patients with ICAS in China.


Options:
A: Arm Label: intensive medical management plus stenting; Type: EXPERIMENTAL; Interventions: Device: intracranial angioplasty and stenting | Arm Label: intensive medical management alone; Type: EXPERIMENTAL; Interventions: Other: intensive medical management | Intervention Type: DEVICE; Name: intracranial angioplasty and stenting; Assigned to Arm(s): intensive medical management plus stenting | Intervention Type: OTHER; Name: intensive medical management; Assigned to Arm(s): intensive medical management alone
B: Arm Label: Carotid Artery Endarterectomy (CEA); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Carotid Endarterectomy (CEA) | Arm Label: Carotid Artery Stenting (CAS); Type: ACTIVE_COMPARATOR; Interventions: Device: Carotid Artery Stenting (CAS) | Intervention Type: PROCEDURE; Name: Carotid Endarterectomy (CEA); Assigned to Arm(s): Carotid Artery Endarterectomy (CEA) | Intervention Type: DEVICE; Name: Carotid Artery Stenting (CAS); Assigned to Arm(s): Carotid Artery Stenting (CAS)
C: Arm Label: Wingspan Stent System; Type: OTHER; Interventions: Device: Wingspan Stent System | Intervention Type: DEVICE; Name: Wingspan Stent System; Assigned to Arm(s): Wingspan Stent System
D: Arm Label: aggressive medical treatment; Type: N/A; Interventions: Device: intravascular stent therapy | Intervention Type: DEVICE; Name: intravascular stent therapy; Assigned to Arm(s): aggressive medical treatment

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer ( ARIEL3 )
Brief Summary: Patients enrolled into this study will be stratified into 3 groups based on gene mutations identified in their tumor tissue. The purpose of this study is to evaluate patient response to maintenance treatment with rucaparib versus placebo. Response to treatment will be analyzed based on homologous recombination (HR) status of tumor samples.


Options:
A: Arm Label: Rucaparib; Type: EXPERIMENTAL; Interventions: Drug: Rucaparib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rucaparib; Assigned to Arm(s): Rucaparib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: olaparib, Drug: paclitaxel, Drug: Drug: carboplatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: paclitaxel, Drug: carboplatin | Intervention Type: DRUG; Name: olaparib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Drug: carboplatin; Assigned to Arm(s): 1
C: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Cediranib, Drug: Olaparib | Arm Label: Arm C; Type: EXPERIMENTAL; Interventions: Drug: Cediranib, Drug: Olaparib | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): Arm B, Arm C | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Arm B, Arm C
D: Arm Label: Control Arm - Chemotherapy only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Procedure/Surgery; Type: EXPERIMENTAL; Interventions: Procedure: Tumor Debulking Surgery (surgery in recurrent ovarian disease) | Intervention Type: PROCEDURE; Name: Tumor Debulking Surgery (surgery in recurrent ovarian disease); Assigned to Arm(s): Procedure/Surgery

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer ( ARIEL3 )
Brief Summary: Patients enrolled into this study will be stratified into 3 groups based on gene mutations identified in their tumor tissue. The purpose of this study is to evaluate patient response to maintenance treatment with rucaparib versus placebo. Response to treatment will be analyzed based on homologous recombination (HR) status of tumor samples.


Options:
A: Arm Label: Rucaparib; Type: EXPERIMENTAL; Interventions: Drug: Rucaparib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rucaparib; Assigned to Arm(s): Rucaparib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: CAELYX; Type: EXPERIMENTAL; Interventions: Drug: CAELYX | Arm Label: Topotecan hydrochloride (HCl); Type: ACTIVE_COMPARATOR; Interventions: Drug: Topotecan HCl | Intervention Type: DRUG; Name: CAELYX; Assigned to Arm(s): CAELYX | Intervention Type: DRUG; Name: Topotecan HCl; Assigned to Arm(s): Topotecan hydrochloride (HCl)
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: AMG 386 Placebo, Drug: Carboplatin | Arm Label: AMG 386; Type: ACTIVE_COMPARATOR; Interventions: Drug: AMG 386, Drug: Paclitaxel, Drug: Carboplatin | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): AMG 386 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): AMG 386, Placebo | Intervention Type: DRUG; Name: AMG 386 Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): AMG 386, Placebo
D: Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Abraxane; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer ( ARIEL3 )
Brief Summary: Patients enrolled into this study will be stratified into 3 groups based on gene mutations identified in their tumor tissue. The purpose of this study is to evaluate patient response to maintenance treatment with rucaparib versus placebo. Response to treatment will be analyzed based on homologous recombination (HR) status of tumor samples.


Options:
A: Arm Label: Rucaparib; Type: EXPERIMENTAL; Interventions: Drug: Rucaparib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rucaparib; Assigned to Arm(s): Rucaparib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo + Carboplatin + Paclitaxel -> Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Other: Placebo to Veliparib | Arm Label: Veliparib + Carboplatin + Paclitaxel -> Placebo; Type: EXPERIMENTAL; Interventions: Drug: Veliparib, Drug: Paclitaxel, Drug: Carboplatin, Other: Placebo to Veliparib | Arm Label: Veliparib + Carboplatin + Paclitaxel -> Veliparib; Type: EXPERIMENTAL; Interventions: Drug: Veliparib, Drug: Paclitaxel, Drug: Carboplatin | Intervention Type: DRUG; Name: Veliparib; Assigned to Arm(s): Veliparib + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Veliparib | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Placebo + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Veliparib | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Placebo + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Veliparib | Intervention Type: OTHER; Name: Placebo to Veliparib; Assigned to Arm(s): Placebo + Carboplatin + Paclitaxel -> Placebo, Veliparib + Carboplatin + Paclitaxel -> Placebo
C: Arm Label: 1/OLAPARIB; Type: EXPERIMENTAL; Interventions: Drug: OLAPARIB | Arm Label: 2/CHEMOTHERAPY; Type: ACTIVE_COMPARATOR; Interventions: Drug: Single agent chemotherapy | Intervention Type: DRUG; Name: OLAPARIB; Assigned to Arm(s): 1/OLAPARIB | Intervention Type: DRUG; Name: Single agent chemotherapy; Assigned to Arm(s): 2/CHEMOTHERAPY
D: Intervention Type: OTHER; Name: screening questionnaire administration; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: annual screening; Assigned to Arm(s): N/A

Answer: A